JPRN-UMIN000031552已完成未知
TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)" - BRAVERY TR
Aichi Cancer Center Hospital0 个研究点目标入组 27 人开始时间: 2018年3月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
TR study of "multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer"colorectal cancerJPRN-UMIN000030505ational Cancer Center Hospital East30
进行中（未招募）
不适用
A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer. - LANDSCAPEEUCTR2008-001084-10-FRFNCLCC
未知
2 期
A phase 2 multicenter clinical study evaluating the safety and efficacy of Nilotinib in patients with Imatinib- resistant/intolerant CML in chronic phaseChronic myelogenous leukemiaJPRN-UMIN000001927Tokyo STI Study Group50
进行中（未招募）
不适用
The long-term antibody persistence of GSK Biologicals’ meningococcal vaccine GSK134612 in healthy toddlersInvasive disease caused by Neisseria meningitidis serogroups A, C W-135 and YMedDRA version: 18.0Level: LLTClassification code 10028910Term: Neisseria meningitides meningitisSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10028911Term: Neisseria meningitidis infection NOSSystem Organ Class: 100000004862EUCTR2012-002719-24-Outside-EU/EEAGlaxoSmithKline Biologicals372
进行中（未招募）
1 期
Encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain.EUCTR2018-002530-20-ESGrupo Español Multidisciplinar de Melanoma63